Genome Insight Raises $23M in Series B-2 Funding

Genome Insight

Genome Insight, a San Diego, CA-based precision healthcare solutions company, raised $23M in Series B-2 funding.

The round was led by Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation. Existing investors participated in this round.

The company intends to use the funds to support its pursuit of bringing whole-genome based precision diagnostics to routine clinical care.

Led by Young Seok Ju, Founder and CEO, Genome Insight is a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease. Its mission is to improve how patients are diagnosed and treated, by unlocking the full potential of personalized genomic data. Earlier this year, the company announced the launch of CancerVision, a test that utilizes whole genome sequencing to offer precise, timely, and medical relevant information that assists in making individualized healthcare decision in cancer. CancerVision integrates advanced bioinformatics and computational techniques to determine whole-genome mutational profiles of individual cancer patients. The information is analyzed and curated for physicians in an easy-to-use format that captures the most relevant and actionable insights for each patient.